A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated Reaction
A Pilot Study of the Effects of Oral Administration of Zavesca® on Anti-rhGAA Immune Response in Subjects With Pompe Disease Receiving rhGAA Enzyme Replacement Therapy
Sponsor: Amicus Therapeutics
Terminated
Participants not interested in enrolling.
A PHASE1 clinical study on Hypersensitivity Reaction and Pompe Disease, this trial is terminated or withdrawn. The trial is conducted by Amicus Therapeutics and has accumulated 9 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2019 — Jan 2021 [monthly]
Terminated PHASE1
-
Nov 2018 — Jan 2019 [monthly]
Terminated PHASE1
Status: Withdrawn → Terminated
▶ Show 4 earlier versions
-
Oct 2018 — Nov 2018 [monthly]
Withdrawn PHASE1
Status: Recruiting → Withdrawn
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amicus Therapeutics
- University of Florida
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.